Both the Pfizer/BioNTech and Moderna vaccines elicit a stronger immune response to the BA.1 strain than the original vaccines.
The European Medicines Agency (EMA) recommends the approval of two new vaccines against the Omicron strain of the coronavirus. It was announced on Thursday, September 1, the press service of the agency reported.
“The EMA Medical Committee recommends allowing two vaccines adapted to provide better protection against COVID-19,” the statement said.
It is noted that both the Pfizer / BioNTech and Moderna vaccines must be approved for vaccination of persons 12 years of age and older who have received at least two vaccines against COVID-19.
“These drugs are versions of the original vaccines Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) adapted to the Omicron BA.1 strain in addition to the original SARS-CoV-2 strain,” explained the agency.
According to scientific studies, both vaccines cause a stronger immune response to the BA.1 strain than the original vaccines.
The EMA’s recommendation is sent to the European Commission, which makes the final decision on the use of new vaccines within the EU.
Recall that in August Ukraine received 100,000 doses of the Janssen coronavirus vaccine. The batch was distributed and delivered to 21 regions of Ukraine and Kyiv.
Earlier, the Ministry of Health recommended the second booster vaccination against COVID-19. Vaccinations are available for people over 60 and adults with chronic illnesses.
News from Correspondent.net on Telegram. Subscribe to our channel Athletistic
Source: korrespondent
I am David Wyatt, a professional writer and journalist for Buna Times. I specialize in the world section of news coverage, where I bring to light stories and issues that affect us globally. As a graduate of Journalism, I have always had the passion to spread knowledge through writing.